Allograft rejection and tubulointerstitial fibrosis in human kidney allografts: Interrogation by urinary cell mRNA profiling

Transplantation Reviews

Volumn 28, Issue 3, 2014, Pages 145-154

  Muthukumar, Thangamani ^a,b   Lee, John R ^a,b   Dadhania, Darshana M ^a,b   Ding, Ruchuang ^a   Sharma, Vijay K ^a   Schwartz, Joseph E ^a,c   Suthanthiran, Manikkam ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MESSENGER RNA;

ACUTE GRAFT REJECTION; BIOLOGY; CHRONIC GRAFT REJECTION; GENE AMPLIFICATION; GRAFT RECIPIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY GRAFT; KIDNEY TUBULE DISORDER; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUBULAR ATROPHY; URINE SEDIMENT; VALIDATION PROCESS; ALLOGRAFT; CLINICAL TRIAL (TOPIC); CYTOLOGY; GENETICS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION;

ALLOGRAFTS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; RNA, MESSENGER;

EID: 84903697203     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2014.05.003     Document Type: Review

References (97)

1. U.S.Renal Data System USRDS 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2013, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Anand S., Bitton A., Gaziano T. The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One 2013, 8:e72860.
3. Kidney disease statistics for the United States, National Kidney and Urologic Diseases Information Clearinghouse, National Institutes of Health, 2012.
4. Tonelli M., Wiebe N., Knoll G., et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011, 11:2093-2109.
5. Wolfe R.A., Ashby V.B., Milford E.L., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
6. Matas A.J., Smith J.M., Skeans M.A., et al. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant 2013, 13:11-46.
7. Pomfret E.A., Sung R.S., Allan J., Kinkhabwala M., Melancon J.K., Roberts J.P. Solving the organ shortage crisis: the 7th Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium. Am J Transplant 2008, 8:745-752.
8. Pallardo Mateu L.M., Sancho Calabuig A., Capdevila Plaza L., Franco Esteve A. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant 2004, 19:iii38-iii42.
9. Meier-Kriesche H.U., Ojo A.O., Hanson J.A., et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000, 70:1098-1100.
10. Cole E.H., Johnston O., Rose C.L., Gill J.S. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008, 3:814-821.
11. Faravardeh A., Eickhoff M., Jackson S., et al. Predictors of graft failure and death in elderly kidney transplant recipients. Transplantation 2013, 96:1089-1096.
12. Shabir S., Halimi J.M., Cherukuri A., et al. Predicting 5-year risk of kidney transplant failure: a prediction instrument using data available at 1 year posttransplantation. Am J Kidney Dis 2014, 63:643-651.
13. Suthanthiran M. Acute rejection of renal allografts: mechanistic insights and therapeutic options. Kidney Int 1997, 51:1289-1304.
14. Suthanthiran M., Strom T.B. Renal transplantation. N Engl J Med 1994, 331:365-376.
15. Nankivell B.J., Alexander S.I. Rejection of the kidney allograft. N Engl J Med 2010, 363:1451-1462.
16. Wood K.J., Zaitsu M., Goto R. Cell mediated rejection. Methods Mol Biol 2013, 1034:71-83.
17. Suthanthiran M., Schwartz J.E., Ding R., et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013, 369:20-31.
18. Hricik D.E., Nickerson P., Formica R.N., et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013, 13:2634-2644.
19. El Ters M., Grande J.P., Keddis M.T., et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013, 13:2334-2341.
20. Strom T.B., Tilney N.L., Carpenter C.B., Busch G.J. Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med 1975, 292:1257-1263.
21. Williams L.E., Merino G.E., Goren G., Najarian J.S., Loken M.K. Detection of canine kidney allograft rejection with 51Cr-labeled lymphocytes. Radiology 1975, 115:205-206.
22. Shresta S., Pham C.T., Thomas D.A., Graubert T.A., Ley T.J. How do cytotoxic lymphocytes kill their targets?. Curr Opin Immunol 1998, 10:581-587.
23. Russell J.H., Ley T.J. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20:323-370.
24. Sharma V.K., Bologa R.M., Li B., et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996, 62:1860-1866.
25. Lipman M.L., Stevens A.C., Strom T.B. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol 1994, 152:5120-5127.
26. Suthanthiran M. Molecular analyses of human renal allografts: differential intragraft gene expression during rejection. Kidney Int Suppl 1997, 58:S15-S21.
27. Strehlau J., Pavlakis M., Lipman M., Maslinski W., Shapiro M., Strom T.B. The intragraft gene activation of markers reflecting T-cell-activation and -cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. Clin Nephrol 1996, 46:30-33.
28. Williams G.M., Hume D.M., Hudson R.P., Morris P.J., Kano K., Milgrom F. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968, 279:611-618.
29. Ahern A.T., Artruc S.B., DellaPelle P., et al. Hyperacute rejection of HLA-AB-identical renal allografts associated with B lymphocyte and endothelial reactive antibodies. Transplantation 1982, 33:103-106.
30. Takemoto S.K., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4:1033-1041.
31. Worthington J.E., Martin S., Al-Husseini D.M., Dyer P.A., Johnson R.W. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003, 75:1034-1040.
32. Hourmant M., Cesbron-Gautier A., Terasaki P.I., et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005, 16:2804-2812.
33. Terasaki P.I., Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005, 80:1194-1197.
34. Gailiunas P., Suthanthiran M., Busch G.J., Carpenter C.B., Garovoy M.R. Role of humoral presenitization in human renal transplant rejection. Kidney Int 1980, 17:638-646.
35. Matignon M., Muthukumar T., Seshan S.V., Suthanthiran M., Hartono C. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation 2012, 94:603-611.
36. Gaston R.S. Our evolving understanding of late kidney allograft failure. Curr Opin Organ Transplant 2011, 16:594-599.
37. Josephson M.A. Late kidney dysfunction in a kidney transplant recipient. Clin J Am Soc Nephrol 2014, 9:590-597.
38. Farris A.B., Colvin R.B. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012, 21:289-300.
39. Bosmans J.L., Ysebaert D.K., Verpooten G.A. Chronic allograft nephropathy: what have we learned from protocol biopsies?. Transplantation 2008, 85:S38-S41.
40. Amer H., Griffin M.D. Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target?. Kidney Int 2014, 85:240-243.
41. Jevnikar A.M., Mannon R.B. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008, 3:S56-S67.
42. Li C., Yang C.W. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009, 5:513-519.
43. Gago M., Cornell L.D., Kremers W.K., Stegall M.D., Cosio F.G. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012, 12:1199-1207.
44. Vitalone M.J., Naesens M., Sigdel T., Li L., Hseih S., Sarwal M.M. The dual role of epithelial-to-mesenchymal transition in chronic allograft injury in pediatric renal transplantation. Transplantation 2011, 92:787-795.
45. Park W.D., Griffin M.D., Cornell L.D., Cosio F.G., Stegall M.D. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010, 21:1987-1997.
46. Mannon R.B., Matas A.J., Grande J., et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010, 10:2066-2073.
47. Heilman R.L., Devarapalli Y., Chakkera H.A., et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010, 10:563-570.
48. Heilman R.L., Chakkera H.A., Reddy K.S., et al. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant 2008, 22:309-315.
49. Gelens M.A., Steegh F.M., van Hooff J.P., et al. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12months postrenal transplant. Clin J Am Soc Nephrol 2012, 7:1010-1017.
50. Prashar Y., Khanna A., Sehajpal P., Sharma V.K., Suthanthiran M. Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. FEBS Lett 1995, 358:109-112.
51. Ahuja S.S., Shrivastav S., Danielpour D., Balow J.E., Boumpas D.T. Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 1995, 60:718-723.
52. Khanna A., Kapur S., Sharma V., Li B., Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation 1997, 63:1037-1039.
53. Shin G.T., Khanna A., Ding R., et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation 1998, 65:313-318.
54. Khanna A., Cairns V., Hosenpud J.D. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999, 67:614-619.
55. McMorrow T., Gaffney M.M., Slattery C., Campbell E., Ryan M.P. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2005, 20:2215-2225.
56. Slattery C., Ryan M.P., McMorrow T. Protein kinase C beta overexpression induces fibrotic effects in human proximal tubular epithelial cells. Int J Biochem Cell Biol 2008, 40:2218-2229.
57. Sharma V.K., Bologa R.M., Xu G.P., et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996, 49:1297-1303.
58. Pribylova-Hribova P., Kotsch K., Lodererova A., et al. TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction. Kidney Int 2006, 69:1872-1879.
59. Nogare A.L., Dalpiaz T., Pedroso J.A., et al. Expression of fibrosis-related genes in human renal allografts with interstitial fibrosis and tubular atrophy. J Nephrol 2013, 26:1179-1187.
60. Ben-Dov I.Z., Muthukumar T., Morozov P., Mueller F.B., Tuschl T., Suthanthiran M. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012, 94:1086-1094.
61. Kers J., Xu-Dubois Y.C., Rondeau E., et al. Intragraft tubular vimentin and CD44 expression correlate with long-term renal allograft function and interstitial fibrosis and tubular atrophy. Transplantation 2010, 90:502-509.
62. Hertig A., Anglicheau D., Verine J., et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008, 19:1584-1591.
63. Guan Q., Li S., Gao S., Chen H., Nguan C.Y., Du C. Reduction of chronic rejection of renal allografts by anti-transforming growth factor-beta antibody therapy in a rat model. Am J Physiol Renal Physiol 2013, 305:F199-F207.
64. Wilczek H.E. Percutaneous needle biopsy of the renal allograft. A clinical safety evaluation of 1129 biopsies. Transplantation 1990, 50:790-797.
65. Schwarz A., Gwinner W., Hiss M., Radermacher J., Mengel M., Haller H. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005, 5:1992-1996.
66. Furness P.N., Philpott C.M., Chorbadjian M.T., et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 2003, 76:969-973.
67. Gloor J.M., Cohen A.J., Lager D.J., et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002, 73:1965-1968.
68. U.S.Renal Data System USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2007, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
69. Lee J.R., Muthukumar T., Dadhania D., et al. Urinary cell mRNA profiles predictive of human kidney allograft status. Immunol Rev 2014, 258:218-240.
70. Li B., Hartono C., Ding R., et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001, 344:947-954.
71. Ding R., Li B., Muthukumar T., et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 2003, 75:1307-1312.
72. Muthukumar T., Ding R., Dadhania D., et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 2003, 75:1565-1570.
73. Tatapudi R.R., Muthukumar T., Dadhania D., et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004, 65:2390-2397.
74. Muthukumar T., Dadhania D., Ding R., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005, 353:2342-2351.
75. Afaneh C., Muthukumar T., Lubetzky M., et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation 2010, 90:1381-1387.
76. Kotsch K., Mashreghi M.F., Bold G., et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 2004, 77:1866-1875.
77. Strom T.B., Suthanthiran M. Prospects and applicability of molecular diagnosis of allograft rejection. Semin Nephrol 2000, 20:103-107.
78. Medeiros M., Sharma V.K., Ding R., et al. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J Immunol Methods 2003, 279:135-142.
79. Li B., Sehajpal P.K., Khanna A., et al. Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991, 174:1259-1262.
80. Ding R., Medeiros M., Dadhania D., et al. Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation 2002, 74:987-994.
81. Cepek K.L., Parker C.M., Madara J.L., Brenner M.B. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol 1993, 150:3459-3470.
82. Hadley G.A., Bartlett S.T., Via C.S., Rostapshova E.A., Moainie S. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. J Immunol 1997, 159:3748-3756.
83. Robertson H., Wong W.K., Talbot D., Burt A.D., Kirby J.A. Tubulitis after renal transplantation: demonstration of an association between CD103+ T cells, transforming growth factor beta1 expression and rejection grade. Transplantation 2001, 71:306-313.
84. Hancock W.W., Gao W., Faia K.L., Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000, 12:511-516.
85. Hancock W.W., Lu B., Gao W., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192:1515-1520.
86. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
87. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
88. Graca L., Cobbold S.P., Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002, 195:1641-1646.
89. Lee I., Wang L., Wells A.D., Dorf M.E., Ozkaynak E., Hancock W.W. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005, 201:1037-1044.
90. Burrell B.E., Lu G., Li X.C., Bishop D.K. OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J Immunol 2009, 182:379-390.
91. Fife B.T., Pauken K.E., Eagar T.N., et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009, 10:1185-1192.
92. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.
93. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
94. Roge R., Thorsen J., Torring C., Ozbay A., Moller B.K., Carstens J. Commonly used reference genes are actively regulated in in vitro stimulated lymphocytes. Scand J Immunol 2007, 65:202-209.
95. Anglicheau D., Muthukumar T., Hummel A., et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation 2012, 93:1136-1146.
96. Keslar K.S., Lin M., Zmijewska A.A., et al. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. Am J Transplant 2013, 13:1891-1897.
97. Anglicheau D., Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008, 86:192-199.